Relation of BMI and Postmenopausal Duration With Antioxidant and Anti-Inflammatory Effects of Raloxifene Treatment in Women With Osteoporosis: A Preliminary Report

Basit Öğe Kaydı
dc.contributor.authorAkcay, Yasemin
dc.contributor.authorEyigor, Sibel
dc.contributor.authorIlanbey, Bilal
dc.contributor.authorKaradeniz, Muammer
dc.contributor.authorKirazli, Yesim
dc.contributor.authorSozmen, Eser
dc.date.accessioned2019-10-27T21:43:55Z
dc.date.available2019-10-27T21:43:55Z
dc.date.issued2012
dc.departmentEge Üniversitesien_US
dc.description.abstractObjective: We have not identified any objective evidence in the literature about the effects of raloxifene treatment on the antioxidant and anti-inflammatory markers. We investigated the antioxidant/anti-inflammatory effects of raloxifene and the association of its antioxidant/anti-inflammatory effects with body mass index (BMI) and postmenopausal period in women with osteoporosis (OP). Materials and Methods: Fourteen postmenopausal women with OP were enrolled in this study. Raloxifene hydrochloride 60 mg/day was administered for 6 months. The oxidant/antioxidant state was evaluated by measuring erythrocyte catalase (e-CAT) and paraoxonase (PON1) activities, levels of thiobarbituric acid (e-TBARS), serum diene, total antioxidant activity (AOA), trolox equivalent antioxidant capacity (TEAC), ferric reducing ability of plasma (FRAP) and anti-inflammatory effects were assessed by measuring tumor necrosis factor (TNF)-alpha, Interleukin (IL-6), IL-18, IL-10 and adiponectin levels. Plasma cytokine (TNF-alpha, IL-6, IL-10, IL-18) levels were measured by ELISA kits and antioxidant parameters were determined by spectrophotometry. Serum levels of all parameters were measured at baseline and end of the study. Results: IL-6 level was significantly decreased but IL-10 and PON1 levels were significantly increased after the study treatment (p<0.05). Raloxifene treatment significantly decreased IL-6 levels when postmenopausal period was longer than 10 years and BMI was <30 kg/m(2) (p<0.05). Conclusion: Raloxifene resulted in a significant decrease in pro-inflammatory cytokine IL-6 and significant increases in anti-inflammatory cytokine IL-10 and antioxidant PON1 levels in women with OP. BMI and postmenopausal period are both associated with anti-inflammatory and antioxidant effects of raloxifene in postmenopausal period. Turk J Phys Med Rehab 2012;58:29-35.en_US
dc.identifier.doi10.4274/tftr.61687
dc.identifier.endpage35en_US
dc.identifier.issn1302-0234
dc.identifier.issue1en_US
dc.identifier.startpage29en_US
dc.identifier.urihttps://doi.org/10.4274/tftr.61687
dc.identifier.urihttps://hdl.handle.net/11454/47168
dc.identifier.volume58en_US
dc.identifier.wosWOS:000304239400007en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.publisherGalenos Yayinciliken_US
dc.relation.ispartofTurkiye Fiziksel Tip Ve Rehabilitasyon Dergisi-Turkish Journal of Physical Medicine and Rehabilitationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectRaloxifeneen_US
dc.subjectanti-inflammatory antioxidant effecten_US
dc.titleRelation of BMI and Postmenopausal Duration With Antioxidant and Anti-Inflammatory Effects of Raloxifene Treatment in Women With Osteoporosis: A Preliminary Reporten_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu